Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycaemic agents; Median follow-up 29 months

Practical Diabetes International

Volumn 19, Issue 8, 2002, Pages 245-249

  Furlong, N J ^a   McNulty, S J ^b   O'Brien, S V ^b   Hardy, K J ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b WHISTON HOSPITAL   (United Kingdom)

Author keywords

Combination therapy; Metformin; Sulphonylurea; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; DIABETES CONTROL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HEALTH CARE; HUMAN; HYPOGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL RESEARCH; NIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; WEIGHT GAIN; WELLBEING;

EID: 0036808738     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.399     Document Type: Article

References (14)

1. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-965.
3. VA CSDM Group. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. Diabetes Care 1998; 21: 574-578.
4. Chow C-C, Sorensen J, Tsang L, Cockram C. Comparison of insulin with or without continuation of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-314.
5. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen MR. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.
6. Yki-Järvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila, M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.
7. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
8. Yki-Järvinen et al. Effect of obesity on the response to insulin therapy in non-insulin-dependent diabetes mellitus. Clin Endocrinol Metab 1997; 82: 4037-4043.
9. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24 (4): 758-767.
10. Riddle MC, Rosenstock J. Treatment to target study: insulin glargine vs. NPH insulin added to oral therapy of type 2 diabetes. Successful control with less hypoglycaemia. Diabetes 2002; 51 (Suppl 2): A113.
11. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime NPH insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23 (8): 1130-1136.
12. Leibowitz G, Cerasi E. Sulfonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing. Diabetologia 1996; 39: 503-514.
13. Berger M, Jorgens V, Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999; 22 (suppl. 3): C71-C75.
14. Muhlhauser I, Sawicki P, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia 1997; 40: 1492-1493.